Transcriptional control of the human high mobility group A1 gene: Basal and oncogenic Ras-regulated expression

Cancer Research

Volumn 67, Issue 10, 2007, Pages 4620-4629

  Cleynen, Isabelle ^a   Huysmans, Christel ^a   Sasazuki, Takehiko ^b   Shirasawa, Senji ^b   Van De Ven, Wim ^a   Peeters, Kristel ^a,c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b FUKUOKA UNIVERSITY   (Japan)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE TRIPHOSPHATASE; HIGH MOBILITY GROUP A PROTEIN; HIGH MOBILITY GROUP A1A PROTEIN; HIGH MOBILITY GROUP A1B PROTEIN; HIGH MOBILITY GROUP A1C PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR SP1;

ARTICLE; BINDING SITE; CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; COLON CANCER; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE; ONCOGENE RAS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; UPREGULATION; WESTERN BLOTTING;

BINDING SITES; COLONIC NEOPLASMS; ENHANCER ELEMENTS (GENETICS); GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HMGA1A PROTEIN; HUMANS; PROMOTER REGIONS (GENETICS); RAS PROTEINS; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 34250330247     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4325     Document Type: Article

References (50)

1. Friedmann M, Holth LT, Zoghbi HY, Reeves R. Organization, inducible-expression, and chromosome localization of the human HMG-I(Y) nonhistone protein gene. Nucleic Acids Res 1993;21:4259-67.
2. Chau KY, Patel UA, Lee KL, Lam HY, Crane-Robinson C. The gene for the human architectural transcription factor HMGI-C consists of five exons each coding for a distinct functional element. Nucleic Acids Res 1995;23:4262-6.
3. Reeves R, Beckerbauer L. HMG1/Y proteins: flexible regulators of transcription and chromatin structure. Biochim Biophys Acta 2001;1519:13-29.
4. Reeves R. Structure and function of the HMGI(Y) family of architectural transcription factors. Environ Health Perspect 2000;108 Suppl 5:803-9.
5. Johnson KR, Lehn DA, Elton TS, Barr PJ, Reeves R. Complete murine cDNA sequence, genomic structure, and tissue expression of the high mobility group protein HMG-I(Y). J Biol Chem 1988;263:18338-42.
6. Chiappetta G, Avantaggiato V, Visconti R, et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 1996;13:2439-46.
7. Giancotti V, Pani B, D'Andrea P, et al. Elevated levels of a specific class of nuclear phosphoproteins in cells transformed with v-ras and v-mos oncogenes and by cotransfection with c-myc and polyoma middle T genes. EMBO J 1987;6:1981-7.
8. Bussemakers MJ, van de Ven WJ, Debruyne FM, Schalken JA. Identification of high mobility group protein I(Y) as potential progression marker for prostate cancer by differential hybridization analysis. Cancer Res 1991;51:606-11.
9. Chiappetta G, Bandiera A, Berlingieri MT, et al. The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. Oncogene 1995;10:1307-14.
10. Kim DH, Park YS, Park CJ, et al. Expression of the HMGI(Y) gene in human colorectal cancer. Int J Cancer 1999;84:376-80.
11. Chiappetta G, Manfioletti G, Pentimalli F, et al. High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases. Int J Cancer 2001;91:147-51.
12. Tamimi Y, van der Poel HG, Karthaus HF, Debruyne FM, Schalken JA. A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization. Br J Cancer 1996;74:573-8.
13. Bandiera A, Bonifacio D, Manfioletti G, et al. Expression of HMGI(Y) proteins in squamous intraepithelial and invasive lesions of the uterine cervix. Cancer Res 1998;58:426-31.
14. Masciullo V, Baldassarre G, Pentimalli F, et al. HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis 2003;24:1191-8.
15. Abe N, Watanabe T, Izumisato Y, et al. Diagnostic significance of high mobility group I(Y) protein expression in intraductal papillary mucinous tumors of the pancreas. Pancreas 2002;25:198-204.
16. Nam ES, Kim DH, Cho SJ, et al. Expression of HMGI(Y) associated with malignant phenotype of human gastric tissue, Histopathology 2003;42:466-71.
17. Chang ZG, Yang LY, Wang W, et al. Determination of high mobility group Al1 (HMGA1) expression in hepatocellular carcinoma: a potential prognostic marker. Dig Dis Sci 2005;50:1764-70.
18. Liu WM, Guerra-Vladusic FK, Kurakata S, Lupu R, Kohwi-Shigematsu T. HMG-I(Y) recognizes base-unpair-ing regions of matrix attachment sequences and its increased expression is directly linked to metastatic breast cancer phenotype. Cancer Res 1999;59:5695-703.
19. Dolde CE, Mukherjee M, Cho C, Resar LM. HMG-I/Y in human breast cancer cell lines. Breast Cancer Res Treat 2002;71:181-91.
20. Pierantoni GM, Agosti V, Fedele M, et al. High-mobility group A1 proteins are overexpressed in human leukaemias. Biochem J 2003;372:145-50.
21. Wood LJ, Maher JF, Bunton TE, Resar LM. The oncogenic properties of the HMG-I gene family. Cancer Res 2000;60:4256-61.
22. Treff NR, Pouchnik D, Dement GA, Britt RL, Reeves R. High-mobility group Ala protein regulates Ras/ERK signaling in MCF-7 human breast cancer cells. Oncogene 2004;23:777-85.
23. Xu Y, Sumter TF, Bhattacharya R, et al. The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. Cancer Res 2004;64:3371-5.
24. Ogram SA, Reeves R. Differential regulation of a multipromoter gene. Selective 12-O-tetradecanoylphorbol-13-acetate induction of a single transcription start site in the HMG-I/Y gene. J Biol Chem 1995;270:14235-42.
25. Kast C, Wang M, Whiteway M. The ERK/MAPK pathway regulates the activity of the human tissue factor pathway inhibitor-2 promoter. J Biol Chem 2003;278:6787-94.
26. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
27. Koeffler HP, McCormick F, Denny C. Molecular mechanisms of cancer. West J Med 1991;155:505-14.
28. Kolibaba KS, Druker BJ. Protein tyrosine kinases and cancer. Biochim Biophys Acta 1997;1333:F217-48.
29. Giehl K. Oncogenic Ras in tumour progression and metastasis. Biol Chem 2005;386:193-205.
30. Declercq J, Van Dyck F, Braem CV, et al. Salivary gland tumors in transgenic mice with targeted PLAG1 proto-oncogene overexpression. Cancer Res 2005;65:4544-53.
31. Crombez KR, Vanoirbeek EM, Van de Ven WJ, Petit MM. Transactivation functions of the tumor-specific HMGA2/LPP fusion protein are augmented by wild-type HMGA2. Mol Cancer Res 2005;3:63-70.
32. Sambrook J, Russell DW. Molecular cloning: a laboratory manual. 3rd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2001.
33. Wadman IA, Osada H, Grutz GG, et al. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1, and Ldb1/NLI proteins. EMBO J 1997;16:3145-57.
34. Pedulla ML, Treff NR, Resar LM, Reeves R. Sequence and analysis of the murine Hmgiy (Hmgal) gene locus. Gene 2001;271:51-8.
35. Pugh BF, Tjian R. Diverse transcriptional functions of the multisubunit eukaryotic TFHD complex. J Biol Chem 1992;267:679-82.
36. Quandt K, Freeh K, Karas H, Wingender E, Werner T. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 1995;23:4878-84.
37. Blume SW, Snyder RC, Ray R, Thomas S, Koller CA, Miller DM. Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J Clin Invest 1991;88:1613-21.
38. Hommura F, Katabami M, Leaner VD, et al. HMG-I/Y is a c-Jun/activator protein-1 target gene and is necessary for c-Jun-induced anchorage-independent growth in Rat1a cells. Mol Cancer Res 2004;2:305-14.
39. Nakata H, Wang SL, Chung DC, Westwick JK, Tillotson LG. Oncogenic ras induces gastrin gene expression in colon cancer. Gastroenterology 1998;115:1144-53.
40. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993;260:85-8.
41. Baba I, Shirasawa S, Iwamoto R, et al. Involvement of deregulated epiregulin expression in tumorigenesis in vivo through activated Ki-Ras signaling pathway in human colon cancer cells. Cancer Res 2000;60:6886-9.
42. Wisniewski JR, Schwanbeck R. High mobility group 1/Y: multifunctional chromosomal proteins causally involved in tumor progression and malignant transformation [review]. Int J Mol Med 2000;6:409-19.
43. Giannini G, Cerignoli F, Mellone M, et al. High mobility group A1 is a molecular target for MYCN in human neuroblastoma. Cancer Res 2005;65:8308-16.
44. Wood LJ, Mukherjee M, Dolde CE, et al. HMG-I/Y, a new c-Myc target gene and potential oncogene. Mol Cell Biol 2000;20:5490-502.
45. Rumsby P, Davie S. Genetic events in the development of colon cancer. Food Chem Toxicol 1995;33:328-30.
46. Westwick JK, Cox AD, Der CJ, et al. Oncogenic Ras activates c-Jun via a separate pathway from the activation of extracellular signal-regulated kinases. Proc Natl Acad Sci U S A 1994;91:6030-4.
47. Suske G. The Sp-family of transcription factors. Gene 1999;238:291-300.
48. Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Sukhatme VP. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 1997;17:5629-39.
49. Black AR, Black JD, Azizkhan-Clifford J. Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001;188:143-60.
50. Mayor C, Brudno M, Schwartz JR, et al. VISTA: visualizing global DNA sequence alignments of arbitrary length. Bioinformatics 2000;16:1046-7.